Proprietary mRNA and LNP technologies and therapeutics developed using them draw attention on the global stage
SML Biopharm announced on the 3rd that it was the only Korean company invited as a guest speaker at the 4th mRNA-Based Therapeutics Summit Europe, held in Frankfurt, Germany from January 28 to 30, where it presented its innovative mRNA platform technology and the research outcomes of therapeutic development using it.
The conference was held against the backdrop of mRNA-based therapeutics becoming an important research platform in the global pharmaceutical and biotech industry, as their application has expanded beyond vaccines to oncology, rare diseases, and infectious disease treatments since the COVID-19 pandemic.
Global companies such as Moderna, BioNTech, Sanofi, and CureVac participated, focusing on next-generation mRNA therapeutic technologies and their clinical applicability. The latest research findings and innovative technologies were shared, and active exchanges among industry experts discussed opportunities for collaboration.
Dr. Young-chan Ahn, head of business development at SML Biopharm, gave a presentation at the conference titled "Harnessing In Vivo Therapeutic Antibody Development Enabled by mRNA-LNP Technology."
Focusing on the case study of developing an antibody therapy for severe fever with thrombocytopenia syndrome (SFTS), he explained how mRNA-LNP technology can be applied in the fields of antibody and bispecific antibody therapeutics, and discussed the present and future of mRNA-based vaccine and therapeutic technology based on the latest research data.
In particular, SML Biopharm’s in vivo therapeutic antibody development results attracted significant interest from multiple biotech companies. SML Biopharm CEO Jae-hwan Nam stated, "The mRNA and LNP technologies independently developed by SML Biopharm and the therapeutic development research utilizing them are receiving attention on the global stage," adding, "We will use this as an opportunity to expand collaboration with researchers worldwide."
SML Biopharm has been actively expanding partnerships, including collaborations with numerous domestic and international biotech companies over the past year, and continues to pursue development of personalized cancer vaccines as well as therapies for rare diseases and infectious diseases based on its mRNA platform technology.
Yakup News https://www.yakup.com/news/index.html?mode=view&cat=12&nid=305646 Economy Science https://www.e-science.co.kr/news/articleView.html?idxno=101423 Hans Economy https://www.hansbiz.co.kr/news/articleView.html?idxno=732393 Hit News http://www.hitnews.co.kr/news/articleView.html?idxno=61346 Health In News https://www.healthinnews.co.kr/view.php?ud=2025020315053158996aa9cc43d0_48
